Clinical Updates in RA: New Developments and Insights From Washington

Program Overview

Program Overview (cont)

Dose Reductions in Patients With Rheumatoid Arthritis

Sarilumab Dose Reduction in RA Patients

Findings

Conclusions

Reduction of Corticosteroids or Methotrexate With Adalimumab

Findings

Conclusions

Loss of Therapeutic Response in Patients With Rheumatoid Arthritis

Loss of Response With a TNF Inhibitor and/or Methotrexate in RA

Findings

Conclusions

Association Between Flare and Radiographic Progression in RA

Methods

Findings

Conclusions

Medication Switching in Rheumatoid Arthritis

Background

Switching Between Certolizumab Pegol and Adalimumab After Anti-TNF Failure

Findings

Conclusions

Switching Biologic Therapy in RA Patients

Findings

Findings (cont)

Longer-Term Follow-Up on Therapies for Rheumatoid Arthritis

3-Year Outcomes of Sarilumab in Patients With RA

Methods

Findings

Findings (cont)

Summary

Long-Term Outcomes With Tofacitinib Based on RAPID3 Responses at 6 Months

Outcome Measures

Findings

Findings (cont)

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)